Peribulbar poloxamer for ocular drug delivery

Acta Ophthalmologica

Volumn 86, Issue 1, 2008, Pages 91-96

  Vehanen, Katja ^a   Hornof, Margit ^b   Urtti, Arto ^b   Uusitalo, Hannu ^a,c,d  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

Biopolymer; Drug toxicity; Fluorophotometry; Peribulbar injection

Indexed keywords

6 CARBOXYFLUORESCEIN; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; POLOXAMER; 6-CARBOXYFLUORESCEIN; DEXTRAN; DRUG DERIVATIVE; FLUORESCEIN DERIVATIVE; FLUORESCEIN ISOTHIOCYANATE; FLUORESCENT DYE; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DISSOLUTION; DRUG DELIVERY SYSTEM; FLUOROPHOTOMETRY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INJECTION SITE; NONHUMAN; PRIORITY JOURNAL; RAT; ABSORPTION; ANIMAL; ANTERIOR EYE CHAMBER; EYE; FLUORESCENCE; INJECTION; METABOLISM; TIME; VISUAL SYSTEM FUNCTION; VITREOUS BODY; WISTAR RAT;

ABSORPTION; ANIMALS; ANTERIOR CHAMBER; DEXTRANS; DRUG DELIVERY SYSTEMS; EYE; FLUORESCEIN-5-ISOTHIOCYANATE; FLUORESCEINS; FLUORESCENCE; FLUORESCENT DYES; IMMUNOHISTOCHEMISTRY; INJECTIONS; OCULAR PHYSIOLOGY; POLOXAMER; RATS; RATS, WISTAR; TIME FACTORS; VITREOUS BODY;

EID: 39349100014     PISSN: 1755375X     EISSN: 16000420     Source Type: Journal    
DOI: 10.1111/j.1600-0420.2007.01001.x     Document Type: Article

References (34)

1. Ahuja N, Katare OP & Singh B (2007): Studies on dissolution enhancement and mathematical modelling of drug release of a poorly water-soluble drug using water-soluble carriers. Eur J Pharm Biopharm 65: 26-38.
2. Amrite AC & Kompella UB (2005): Size-dependent disposition of nanoparticles and microparticles following subconjunctival administration. J Pharm Pharmacol 57: 1555-1563.
3. Anderson BC, Pandit NK & Mallapragada SK (2001): Understanding drug release from poly(ethylene oxide)-b-poly(propylene oxide)-b-poly(ethylene oxide) gels. J Control Release 70: 157-167.
4. Ayalasomayajula SP & Kompella UB (2005): Subconjunctivally administered celecoxib-PLGA microparticles sustain retinal drug levels and alleviate diabetes-induced oxidative stress in a rat model. Eur J Pharmacol 511: 191-198.
5. Bochot A, Couvreur P & Fattal E (2000): Intravitreal administration of antisense oligonucleotides: Potential of liposomal delivery. Prog Retin Eye Res 19: 131-147.
6. Carmo A, Cunha-Vaz JG, Carvalho AP & Lopes MC (2000): Nitric oxide synthase activity in retinas from non-insulin-dependent diabetic Goto-Kakizaki rats: Correlation with blood-retinal barrier permeability. Nitric Oxide 4: 590-596.
7. Chakravarthy U, Soubrane G, Bandello F et al. (2006): Evolving European guidance on the medical management of neovascular age-related macular degeneration. Br J Ophthalmol 90: 1188-1196.
8. Chiou GC, Zhou YH, Xuan B, Yamasaki T & Okawara T (1999): Suppression of interleukin-1α-induced uveitis and inhibition of fibroblast-like cell proliferation by synthetic interleukin-1 blockers. J Ocul Pharmacol Ther 15: 351-362.
9. Choi YS, Park SN & Suh H (2005): Adipose tissue engineering using mesenchymal stem cells attached to injectable PLGA spheres. Biomaterials 26: 5855-5863.
10. Chun KW, Lee JB, Kim SH & Park TG (2005): Controlled release of plasmid DNA from photo-cross-linked pluronic hydrogels. Biomaterials 26: 3319-3326.
11. Clark AF & Yorio T (2003): Ophthalmic drug discovery. Nat Rev Drug Discov 2: 448-459.
12. Desai SD & Blanchard J (1998): Evaluation of pluronic F127-based sustained-release ocular delivery systems for pilocarpine using the albino rabbit eye model. J Pharm Sci 87: 1190-1195.
13. Ding S (1998): Recent developments in ophthalmic drug delivery. Pharmaceut Sci Technol Today 1: 328-335.
14. Han YK, Kwon JW, Kim JS, Cho CS, Wee WR & Lee JH (2003): In vitro and in vivo study of lens refilling with poloxamer hydrogel. Br J Ophthalmol 87: 1399-1402.
15. Kabanov AV, Batrakova EV & Alakhov VY (2002b): Pluronic (R) block copolymers as novel polymer therapeutics for drug and gene delivery. J Control Release 82: 189-212.
16. Kabanov AV, Lemieux P, Vinogradov S & Alakhov V (2002a): Pluronic (R) block copolymers: Novel functional molecules for gene therapy. Adv Drug Deliv Rev 54: 223-233.
17. Kim EY, Gao ZG, Park JS, Li H & Han K (2002): RhEGF/HP-β-CD complex in poloxamer gel for ophthalmic delivery. Int J Pharm 233: 159-167.
18. Kompella UB, Bandi N & Ayalasomayajula SP (2003): Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci 44: 1192-1201.
19. Lee SB, Geroski DH, Prausnitz MR & Edelhauser HF (2004): Drug delivery through the sclera: Effects of thickness, hydration and sustained release systems. Exp Eye Res 78: 599-607.
20. Lin HR, Sung KC & Vong WJ (2004): In situ gelling of alginate/ pluronic solutions for ophthalmic delivery of pilocarpine. Biomacromolecules 5: 2358-2365.
21. Lloyd AW, Faragher RG & Denyer SP (2001): Ocular biomaterials and implants. Biomaterials 22: 769-785.
22. Lund F, Solvason N, Grimaldi JC, Parkhouse RM & Howard M (1995): Murine CD38: An immunoregulatory ectoenzyme. Immunol Today 16: 469-473.
23. Mackie EJ, Halfter W & Liverani D (1988): Induction of tenascin in healing wounds. J Cell Biol 107: 2757-2767.
24. Mehta K, Shahid U & Malavasi F (1996): Human CD38, a cell-surface protein with multiple functions. FASEB J 10: 1408-1417.
25. Moghimi SM & Hunter AC (2000): Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends Biotechnol 18: 412-420.
26. Ortiz-Rey JA, Suarez-Penaranda JM, Munoz-Barus JI et.al. (2003): Expression of fibronectin and tenascin as a demonstration of vital reaction in rat skin and muscle. Int J Legal Med 117: 356-360.
27. Peppas NA, Huang Y, Torres-Lugo M, Ward JH & Zhang J (2000): Physicochemical foundations and structural design of hydrogels in medicine and biology. Annu Rev Biomed Eng 2: 9-29.
28. Peyman GA & Ganiban GJ (1995): Delivery systems for intraocular routes. Adv Drug Deliv Rev 16: 107-123.
29. Srivastava SK, Martin DF, Mellow SD, Parks DJ, Dastgheib K & Chan CC (2005): Pathological findings in eyes with the ganciclovir implant. Ophthalmology 112: 780-786.
30. Stolnik S, Illum L & Davis SS (1995): Long circulating microparticulate drug carriers. Adv Drug Deliv Rev 16: 195-214.
31. Tuori A, Virtanen I, Aine E & Uusitalo H (1997): The expression of tenascin and fibronectin in keratoconus, scarred and normal human cornea. Graefes Arch Clin Exp Ophthalmol 235: 222-229.
32. World Health Organization (2004): Magnitude and Causes of Visual Impairment. Fact Sheet No. 282. Geneva: WHO.
33. Wu CC, Chang SW, Chen MS & Lee YT (1995): Early change of vascular permeability in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 15: 529-533.
34. Zhang SX, Sima J, Wang JJ, Shao C, Fant J & Ma JX (2005): Systemic and periocular deliveries of plasminogen kringle 5 reduce vascular leakage in rat models of oxygen-induced retinopathy and diabetes. Curr Eye Res 30: 681-689.